Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| IDEXX LABORATORIES INC /DEIDXX · Entity 3057 | Director | September 06, 2024 | September 09, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
IDEXX LABORATORIES INC /DE
Report date September 06, 2024 · Filed September 09, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 35,651 |
Reported balance
After 2024-09-06 transaction · row 1
1 source rowRow 1 · 2024-09-06 · Gift · Disposed 230,000 · Balance 35,651 |
| Common StockSEC Table I · non-derivative | Indirectby Jonathan W. Ayers 2022 GRAT | 0 |
Reported balance
After 2024-09-06 transaction · row 2
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 2 · 2024-09-06 · Gift · Disposed 302,179 · Balance 0 F1: The reporting person is the grantor and trustee of the Jonathan W. Ayers 2022 GRAT ('2022 GRAT'). The 2022 GRAT is irrevocable, and the reporting person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | Indirectby Jonathan W. Ayers 2024 GRAT | 419,574 |
Reported balance
After 2024-09-06 transaction · row 3
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 3 · 2024-09-06 · Gift · Acquired 419,574 · Balance 419,574 F2: The reporting person is the grantor and trustee of the Jonathan W. Ayers 2024 GRAT ('2024 GRAT'). The 2024 GRAT is irrevocable, and the reporting person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | Indirectby Ayers Family Trust | 122,605 |
Reported balance
After 2024-09-06 transaction · row 4
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 4 · 2024-09-06 · Gift · Acquired 112,605 · Balance 122,605 |
Filing footnotes · ownership attribution and instrument terms
F1: The reporting person is the grantor and trustee of the Jonathan W. Ayers 2022 GRAT ('2022 GRAT'). The 2022 GRAT is irrevocable, and the reporting person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein.
F2: The reporting person is the grantor and trustee of the Jonathan W. Ayers 2024 GRAT ('2024 GRAT'). The 2024 GRAT is irrevocable, and the reporting person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 14, 2020 Filed Aug 18, 2020 21:08 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionCommon Stock | 25,000 | $62.00 | $1,550,000.00 |
DisclosureSEC source: 0001567619-20-015707 · doc1.xml · nonDerivative · entry 1 AYERS JONATHAN W · CIK 0001184149 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 835,467 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 19, 2020 Filed May 20, 2020 21:00 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | SaleCommon Stock | 10,000 | $294.99 | $2,949,900.00 |
DisclosureSEC source: 0001567619-20-010832 · doc1.xml · nonDerivative · entry 3 AYERS JONATHAN W · CIK 0001184149 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · by Ayers Family Trust Disclosed balance after: 10,000 Read SEC document |
| May 18, 2020 Filed May 20, 2020 21:00 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | SaleCommon Stock | 23,000 | $297.29 | $6,837,670.00 |
DisclosureSEC source: 0001567619-20-010832 · doc1.xml · nonDerivative · entry 2 AYERS JONATHAN W · CIK 0001184149 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · by Ayers Family Trust Disclosed balance after: 20,000 Read SEC document |
| May 18, 2020 Filed May 20, 2020 21:00 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | SaleCommon Stock | 5,000 | $297.18 | $1,485,900.00 |
DisclosureSEC source: 0001567619-20-010832 · doc1.xml · nonDerivative · entry 1 AYERS JONATHAN W · CIK 0001184149 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · by Ayers Family Trust Disclosed balance after: 43,000 Read SEC document |
| May 12, 2020 Filed May 13, 2020 21:02 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | SaleCommon Stock | 30,000 | $293.41 | $8,802,300.00 |
DisclosureSEC source: 0001567619-20-009830 · doc1.xml · nonDerivative · entry 2 AYERS JONATHAN W · CIK 0001184149 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · by Ayers Family Trust Disclosed balance after: 48,000 Read SEC document |
| May 11, 2020 Filed May 13, 2020 21:02 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | SaleCommon Stock | 20,000 | $297.80 | $5,956,000.00 |
DisclosureSEC source: 0001567619-20-009830 · doc1.xml · nonDerivative · entry 1 AYERS JONATHAN W · CIK 0001184149 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · by Ayers Family Trust Disclosed balance after: 78,000 Read SEC document |
| May 11, 2020 Filed Aug 28, 2020 21:01 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | GiftCommon Stock | 16,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-20-016146 · doc1.xml · nonDerivative · entry 1 AYERS JONATHAN W · CIK 0001184149 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 794,467 Read SEC document |
| May 08, 2020 Filed May 12, 2020 21:11 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionNon-Qualified Stock Option (right-to-buy) · Derivative | 21,130 | Not disclosed Strike: $62.00 | Not disclosed |
DisclosureSEC source: 0001567619-20-009600 · doc1.xml · derivative · entry 7 AYERS JONATHAN W · CIK 0001184149 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,940 Underlying: Common Stock · 21,130 shares Expires 2024-02-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · price: Not applicable. F5 · derivative.exercise_date: Grant of option to buy 44,535 shares of IDEXX Laboratories, Inc. common stock that became exercisable in five equal annual installments beginning on February 14, 2015 without giving effect to the 2-for-1 stock split of IDEXX Laboratories, Inc. common stock that occurred on June 15, 2015 (the "Stock Split"). The number of derivative securities reported as beneficially owned with respect to this option and its exercise price were adjusted to reflect the Stock Split. Read SEC document |
| May 08, 2020 Filed May 12, 2020 21:11 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | SaleCommon Stock | 2,601 | $293.40 | $763,124.56 |
DisclosureSEC source: 0001567619-20-009600 · doc1.xml · nonDerivative · entry 5 AYERS JONATHAN W · CIK 0001184149 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 810,467 F4 · price: Represents the weighted average price of the shares sold ranging from a low of $293.13 to a high of 294.03 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Read SEC document |
| May 08, 2020 Filed May 12, 2020 21:11 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | SaleCommon Stock | 3,440 | $292.44 | $1,005,993.26 |
DisclosureSEC source: 0001567619-20-009600 · doc1.xml · nonDerivative · entry 4 AYERS JONATHAN W · CIK 0001184149 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 813,068 F3 · price: Represents the weighted average price of the shares sold ranging from a low of $292.07 to a high of $293.01 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Read SEC document |
| May 08, 2020 Filed May 12, 2020 21:11 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | SaleCommon Stock | 9,953 | $291.41 | $2,900,450.51 |
DisclosureSEC source: 0001567619-20-009600 · doc1.xml · nonDerivative · entry 3 AYERS JONATHAN W · CIK 0001184149 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 816,508 F2 · price: Represents the weighted average price of the shares sold ranging from a low of $290.00 to a high of $290.98 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Read SEC document |
| May 08, 2020 Filed May 12, 2020 21:11 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | SaleCommon Stock | 5,136 | $290.59 | $1,492,490.27 |
DisclosureSEC source: 0001567619-20-009600 · doc1.xml · nonDerivative · entry 2 AYERS JONATHAN W · CIK 0001184149 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 826,461 F1 · price: Represents the weighted average price of the shares sold ranging from a low of $290.00 to a high of $290.98 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Read SEC document |
| May 08, 2020 Filed May 12, 2020 21:11 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionCommon Stock | 21,130 | $62.00 | $1,310,060.00 |
DisclosureSEC source: 0001567619-20-009600 · doc1.xml · nonDerivative · entry 1 AYERS JONATHAN W · CIK 0001184149 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 831,597 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 07, 2020 Filed May 8, 2020 21:00 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | SaleCommon Stock | 11,000 | $292.25 | $3,214,750.00 |
DisclosureSEC source: 0001567619-20-009372 · doc1.xml · nonDerivative · entry 3 AYERS JONATHAN W · CIK 0001184149 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · by Ayers Family Trust Disclosed balance after: 98,000 Read SEC document |
| May 06, 2020 Filed May 8, 2020 21:00 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | GrantNon-Qualified Stock Option (right-to-buy) · Derivative | 1,279 | Not disclosed Strike: $283.59 | Not disclosed |
DisclosureSEC source: 0001567619-20-009372 · doc1.xml · derivative · entry 6 AYERS JONATHAN W · CIK 0001184149 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,279 Underlying: Common Stock · 1,279 shares Expires 2030-05-05 F3 · price: Not applicable. F2 · derivative.exercise_date: Grant of option to buy shares of IDEXX Laboratories, Inc. common stock that vest in one installment on the one year anniversary of the date of grant or on the date of the 2021 annual meeting of shareholders, whichever event is earlier. Read SEC document |
| May 06, 2020 Filed May 8, 2020 21:00 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | GrantDeferred Stock Unit · Derivative | 370 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001567619-20-009372 · doc1.xml · derivative · entry 5 AYERS JONATHAN W · CIK 0001184149 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 584 Underlying: Common Stock · 370 shares Expires not disclosed F1 · derivative.exercise_price: Each deferred stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. Deferred stock units vest in one installment on the one year anniversary of the date of grant or on the date of the 2021 annual meeting of shareholders, whichever event is earlier, and are payable as common stock one year following the Director's resignation from the Board of Directors. F3 · price: Not applicable. F1 · derivative.exercise_date: Each deferred stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. Deferred stock units vest in one installment on the one year anniversary of the date of grant or on the date of the 2021 annual meeting of shareholders, whichever event is earlier, and are payable as common stock one year following the Director's resignation from the Board of Directors. F1 · derivative.expiration_date: Each deferred stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. Deferred stock units vest in one installment on the one year anniversary of the date of grant or on the date of the 2021 annual meeting of shareholders, whichever event is earlier, and are payable as common stock one year following the Director's resignation from the Board of Directors. Read SEC document |
| May 06, 2020 Filed May 8, 2020 21:00 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | SaleCommon Stock | 13,600 | $286.07 | $3,890,552.00 |
DisclosureSEC source: 0001567619-20-009372 · doc1.xml · nonDerivative · entry 2 AYERS JONATHAN W · CIK 0001184149 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · by Ayers Family Trust Disclosed balance after: 109,000 Read SEC document |
| May 04, 2020 Filed May 8, 2020 21:00 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | SaleCommon Stock | 15,000 | $268.34 | $4,025,100.00 |
DisclosureSEC source: 0001567619-20-009372 · doc1.xml · nonDerivative · entry 1 AYERS JONATHAN W · CIK 0001184149 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · by Ayers Family Trust Disclosed balance after: 122,600 Read SEC document |
| February 25, 2020 Filed Feb 27, 2020 22:02 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionIncentive Stock Option (right-to-buy) · Derivative | 1,256 | Not disclosed Strike: $79.54 | Not disclosed |
DisclosureSEC source: 0001567619-20-005007 · doc1.xml · derivative · entry 3 AYERS JONATHAN W · CIK 0001184149 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,256 shares Expires 2025-02-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: Not applicable. F1 · derivative.exercise_date: Grant of option to buy 628 shares of Issuer common stock that became exercisable on the fifth anniversary of the date of grant without giving effect to the 2-for-1 stock split of IDEXX Laboratories, Inc. common stock that occurred on June 15, 2015 (the "Stock Split"). The number of derivative securities reported as beneficially owned with respect to this option and its exercise price were adjusted to reflect the Stock Split. Read SEC document |
| February 25, 2020 Filed Feb 27, 2020 22:02 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionCommon Stock | 1,256 | $79.54 | $99,902.24 |
DisclosureSEC source: 0001567619-20-005007 · doc1.xml · nonDerivative · entry 1 AYERS JONATHAN W · CIK 0001184149 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 810,467 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 21, 2020 Filed Feb 24, 2020 22:52 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | SaleCommon Stock | 400 | $280.40 | $112,159.52 |
DisclosureSEC source: 0001567619-20-004735 · doc1.xml · nonDerivative · entry 12 AYERS JONATHAN W · CIK 0001184149 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · by Ayers Family Trust Disclosed balance after: 137,600 Read SEC document |
| February 21, 2020 Filed Feb 24, 2020 22:52 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | GiftCommon Stock | 650 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-20-004735 · doc1.xml · nonDerivative · entry 11 AYERS JONATHAN W · CIK 0001184149 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 809,211 Read SEC document |
| February 20, 2020 Filed Feb 24, 2020 22:52 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionNon-Qualified Stock Option (right-to-buy) · Derivative | 23,000 | Not disclosed Strike: $62.00 | Not disclosed |
DisclosureSEC source: 0001567619-20-004735 · doc1.xml · derivative · entry 13 AYERS JONATHAN W · CIK 0001184149 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,070 Underlying: Common Stock · 23,000 shares Expires 2024-02-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F11 · price: Not applicable. F10 · derivative.exercise_date: Grant of option to buy 44,535 shares of IDEXX Laboratories, Inc. common stock that became exercisable in five equal annual installments beginning on February 14, 2015 without giving effect to the 2-for-1 stock split of IDEXX Laboratories, Inc. common stock that occurred on June 15, 2015 (the "Stock Split"). The number of derivative securities reported as beneficially owned with respect to this option and its exercise price were adjusted to reflect the Stock Split. Read SEC document |
| February 20, 2020 Filed Feb 24, 2020 22:52 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | SaleCommon Stock | 928 | $290.24 | $269,339.56 |
DisclosureSEC source: 0001567619-20-004735 · doc1.xml · nonDerivative · entry 10 AYERS JONATHAN W · CIK 0001184149 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 809,861 F9 · price: Represents the weighted average price of the shares sold ranging from a low of $290.07 to a high of $290.39 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Read SEC document |
| February 20, 2020 Filed Feb 24, 2020 22:52 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | SaleCommon Stock | 300 | $288.67 | $86,600.10 |
DisclosureSEC source: 0001567619-20-004735 · doc1.xml · nonDerivative · entry 9 AYERS JONATHAN W · CIK 0001184149 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 810,789 F8 · price: Represents the weighted average price of the shares sold ranging from a low of $288.60 to a high of $288.71 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Read SEC document |
| February 20, 2020 Filed Feb 24, 2020 22:52 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | SaleCommon Stock | 1,424 | $287.72 | $409,707.58 |
DisclosureSEC source: 0001567619-20-004735 · doc1.xml · nonDerivative · entry 8 AYERS JONATHAN W · CIK 0001184149 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 811,089 F7 · price: Represents the weighted average price of the shares sold ranging from a low of $287.54 to a high of $288.53 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Read SEC document |
| February 20, 2020 Filed Feb 24, 2020 22:52 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | SaleCommon Stock | 4,600 | $286.81 | $1,319,344.40 |
DisclosureSEC source: 0001567619-20-004735 · doc1.xml · nonDerivative · entry 7 AYERS JONATHAN W · CIK 0001184149 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 812,513 F6 · price: Represents the weighted average price of the shares sold ranging from a low of $286.52 to a high of $287.51 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Read SEC document |
| February 20, 2020 Filed Feb 24, 2020 22:52 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | SaleCommon Stock | 8,375 | $285.98 | $2,395,082.50 |
DisclosureSEC source: 0001567619-20-004735 · doc1.xml · nonDerivative · entry 6 AYERS JONATHAN W · CIK 0001184149 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 817,113 F5 · price: Represents the weighted average price of the shares sold ranging from a low of $285.51 to a high of $286.42 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Read SEC document |
| February 20, 2020 Filed Feb 24, 2020 22:52 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | SaleCommon Stock | 1,400 | $284.04 | $397,661.60 |
DisclosureSEC source: 0001567619-20-004735 · doc1.xml · nonDerivative · entry 5 AYERS JONATHAN W · CIK 0001184149 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 825,488 F4 · price: Represents the weighted average price of the shares sold ranging from a low of $283.54 to a high of 284.48 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Read SEC document |
| February 20, 2020 Filed Feb 24, 2020 22:52 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | SaleCommon Stock | 1,000 | $282.69 | $282,690.00 |
DisclosureSEC source: 0001567619-20-004735 · doc1.xml · nonDerivative · entry 4 AYERS JONATHAN W · CIK 0001184149 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 826,888 F3 · price: Represents the weighted average price of the shares sold ranging from a low of $282.30 to a high of $283.08 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Read SEC document |
| February 20, 2020 Filed Feb 24, 2020 22:52 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | SaleCommon Stock | 400 | $281.30 | $112,520.00 |
DisclosureSEC source: 0001567619-20-004735 · doc1.xml · nonDerivative · entry 3 AYERS JONATHAN W · CIK 0001184149 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 827,888 F2 · price: Represents the weighted average price of the shares sold ranging from a low of $281.16 to a high of $281.72 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Read SEC document |
| February 20, 2020 Filed Feb 24, 2020 22:52 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | SaleCommon Stock | 4,573 | $280.34 | $1,282,003.97 |
DisclosureSEC source: 0001567619-20-004735 · doc1.xml · nonDerivative · entry 2 AYERS JONATHAN W · CIK 0001184149 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 828,288 F1 · price: Represents the weighted average price of the shares sold ranging from a low of $280.04 to a high of $281.00 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Read SEC document |
| February 20, 2020 Filed Feb 24, 2020 22:52 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionCommon Stock | 23,000 | $62.00 | $1,426,000.00 |
DisclosureSEC source: 0001567619-20-004735 · doc1.xml · nonDerivative · entry 1 AYERS JONATHAN W · CIK 0001184149 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 832,861 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 19, 2020 Filed Feb 21, 2020 22:23 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | SaleCommon Stock | 500 | $295.21 | $147,603.50 |
DisclosureSEC source: 0001567619-20-004624 · doc1.xml · nonDerivative · entry 15 AYERS JONATHAN W · CIK 0001184149 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 810,361 F11 · price: Represents the weighted average price of the shares sold ranging from a low of $295.07 to a high of $295.64 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Read SEC document |
| February 19, 2020 Filed Feb 21, 2020 22:23 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | SaleCommon Stock | 7,827 | $294.84 | $2,307,727.55 |
DisclosureSEC source: 0001567619-20-004624 · doc1.xml · nonDerivative · entry 14 AYERS JONATHAN W · CIK 0001184149 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 818,188 F10 · price: Represents the weighted average price of the shares sold ranging from a low of $294.07 to a high of $295.06 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Read SEC document |
| February 19, 2020 Filed Feb 21, 2020 22:23 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | SaleCommon Stock | 6,846 | $293.78 | $2,011,196.66 |
DisclosureSEC source: 0001567619-20-004624 · doc1.xml · nonDerivative · entry 13 AYERS JONATHAN W · CIK 0001184149 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 825,034 F9 · price: Represents the weighted average price of the shares sold ranging from a low of $293.06 to a high of $294.035 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Read SEC document |
| February 19, 2020 Filed Feb 21, 2020 22:23 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | SaleCommon Stock | 1,406 | $292.71 | $411,543.23 |
DisclosureSEC source: 0001567619-20-004624 · doc1.xml · nonDerivative · entry 12 AYERS JONATHAN W · CIK 0001184149 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 826,440 F8 · price: Represents the weighted average price of the shares sold ranging from a low of $292.00 to a high of $292.97 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Read SEC document |
| February 19, 2020 Filed Feb 21, 2020 22:23 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | SaleCommon Stock | 100 | $290.16 | $29,016.00 |
DisclosureSEC source: 0001567619-20-004624 · doc1.xml · nonDerivative · entry 11 AYERS JONATHAN W · CIK 0001184149 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 826,540 Read SEC document |
| February 19, 2020 Filed Feb 21, 2020 22:23 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | SaleCommon Stock | 805 | $289.48 | $233,034.78 |
DisclosureSEC source: 0001567619-20-004624 · doc1.xml · nonDerivative · entry 10 AYERS JONATHAN W · CIK 0001184149 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 827,345 F7 · price: Represents the weighted average price of the shares sold ranging from a low of $289.02 to a high of $289.97 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Read SEC document |
| February 19, 2020 Filed Feb 21, 2020 22:23 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | SaleCommon Stock | 634 | $288.43 | $182,864.94 |
DisclosureSEC source: 0001567619-20-004624 · doc1.xml · nonDerivative · entry 9 AYERS JONATHAN W · CIK 0001184149 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 827,979 F6 · price: Represents the weighted average price of the shares sold ranging from a low of $288.00 to a high of $288.99 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Read SEC document |
| February 19, 2020 Filed Feb 21, 2020 22:23 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | SaleCommon Stock | 7,042 | $295.02 | $2,077,501.97 |
DisclosureSEC source: 0001567619-20-004624 · doc1.xml · nonDerivative · entry 8 AYERS JONATHAN W · CIK 0001184149 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 827,979 F5 · price: Represents the weighted average price of the shares sold ranging from a low of $294.56 to a high of $295.44 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Read SEC document |
| February 19, 2020 Filed Feb 21, 2020 22:23 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | SaleCommon Stock | 8,104 | $293.94 | $2,382,070.31 |
DisclosureSEC source: 0001567619-20-004624 · doc1.xml · nonDerivative · entry 7 AYERS JONATHAN W · CIK 0001184149 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 835,021 F4 · price: Represents the weighted average price of the shares sold ranging from a low of $293.50 to a high of 294.50 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Read SEC document |
| February 19, 2020 Filed Feb 21, 2020 22:23 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | SaleCommon Stock | 3,000 | $293.04 | $879,120.30 |
DisclosureSEC source: 0001567619-20-004624 · doc1.xml · nonDerivative · entry 6 AYERS JONATHAN W · CIK 0001184149 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 843,125 F3 · price: Represents the weighted average price of the shares sold ranging from a low of $292.48 to a high of $293.48 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Read SEC document |
| February 19, 2020 Filed Feb 21, 2020 22:23 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | SaleCommon Stock | 100 | $291.46 | $29,146.00 |
DisclosureSEC source: 0001567619-20-004624 · doc1.xml · nonDerivative · entry 5 AYERS JONATHAN W · CIK 0001184149 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 846,125 Read SEC document |
| February 19, 2020 Filed Feb 21, 2020 22:23 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | SaleCommon Stock | 100 | $290.35 | $29,035.00 |
DisclosureSEC source: 0001567619-20-004624 · doc1.xml · nonDerivative · entry 4 AYERS JONATHAN W · CIK 0001184149 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 846,225 Read SEC document |
| February 19, 2020 Filed Feb 21, 2020 22:23 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | SaleCommon Stock | 900 | $289.52 | $260,564.49 |
DisclosureSEC source: 0001567619-20-004624 · doc1.xml · nonDerivative · entry 3 AYERS JONATHAN W · CIK 0001184149 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 846,325 F2 · price: Represents the weighted average price of the shares sold ranging from a low of $289.04 to a high of $290.02 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Read SEC document |
| February 19, 2020 Filed Feb 21, 2020 22:23 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | SaleCommon Stock | 758 | $288.50 | $218,682.47 |
DisclosureSEC source: 0001567619-20-004624 · doc1.xml · nonDerivative · entry 2 AYERS JONATHAN W · CIK 0001184149 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 847,225 F1 · price: Represents the weighted average price of the shares sold ranging from a low of $288.00 to a high of $289.00 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Read SEC document |
| February 19, 2020 Filed Feb 21, 2020 22:23 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | SaleCommon Stock | 1,021 | $288.00 | $294,048.00 |
DisclosureSEC source: 0001567619-20-004624 · doc1.xml · nonDerivative · entry 1 AYERS JONATHAN W · CIK 0001184149 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 847,983 Read SEC document |
| February 19, 2020 Filed Feb 24, 2020 22:51 UTC Amendment | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | SaleCommon Stock | 500 | $295.21 | $147,603.50 |
DisclosureSEC source: 0001567619-20-004734 · doc1.xml · nonDerivative · entry 15 AYERS JONATHAN W · CIK 0001184149 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 809,861 F11 · price: Represents the weighted average price of the shares sold ranging from a low of $295.07 to a high of $295.64 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. F12 · balance_after: The Form 4 has been amended to correct the amount of securities beneficially owned following the reported transactions. Read SEC document |
| February 19, 2020 Filed Feb 24, 2020 22:51 UTC Amendment | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | SaleCommon Stock | 7,827 | $294.84 | $2,307,727.55 |
DisclosureSEC source: 0001567619-20-004734 · doc1.xml · nonDerivative · entry 14 AYERS JONATHAN W · CIK 0001184149 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 810,361 F10 · price: Represents the weighted average price of the shares sold ranging from a low of $294.07 to a high of $295.06 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.